Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1889 1
1893 1
1927 1
1932 2
1933 1
1946 1
1947 3
1948 4
1949 5
1950 8
1951 5
1952 5
1953 5
1954 8
1955 12
1956 10
1957 6
1958 11
1959 12
1960 9
1961 11
1962 16
1963 20
1964 17
1965 26
1966 16
1967 21
1968 18
1969 10
1970 11
1971 20
1972 8
1973 15
1974 19
1975 14
1976 26
1977 16
1978 26
1979 29
1980 32
1981 26
1982 27
1983 30
1984 37
1985 30
1986 33
1987 30
1988 35
1989 29
1990 29
1991 34
1992 32
1993 33
1994 43
1995 45
1996 36
1997 30
1998 37
1999 40
2000 26
2001 40
2002 34
2003 30
2004 39
2005 42
2006 29
2007 39
2008 50
2009 35
2010 61
2011 59
2012 54
2013 67
2014 53
2015 46
2016 54
2017 49
2018 48
2019 41
2020 41
2021 48
2022 50
2023 46
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

2,096 results

Results by year

Filters applied: . Clear all
Page 1
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Adekola K, Anderson LD Jr, Baljevic M, Baz R, Campagnaro E, Castillo JJ, Costello C, D'Angelo C, Devarakonda S, Elsedawy N, Garfall A, Godby K, Hillengass J, Holmberg L, Htut M, Huff CA, Hultcrantz M, Kang Y, Larson S, Lee HC, Liedtke M, Martin T, Omel J, Robinson T, Rosenberg A, Sborov D, Schroeder MA, Sherbenou D, Suvannasankha A, Valent J, Varshavsky-Yanovsky AN, Kumar R, Snedeker J. Kumar SK, et al. Among authors: anderson ld jr. J Natl Compr Canc Netw. 2023 Dec;21(12):1281-1301. doi: 10.6004/jnccn.2023.0061. J Natl Compr Canc Netw. 2023. PMID: 38081133
Risk factors for venous thromboembolism.
Anderson FA Jr, Spencer FA. Anderson FA Jr, et al. Circulation. 2003 Jun 17;107(23 Suppl 1):I9-16. doi: 10.1161/01.CIR.0000078469.07362.E6. Circulation. 2003. PMID: 12814980 Review.
Preface.
Anderson RS Jr, Magidson PD, Khoujah D. Anderson RS Jr, et al. Emerg Med Clin North Am. 2021 May;39(2):xv-xvi. doi: 10.1016/j.emc.2021.02.001. Emerg Med Clin North Am. 2021. PMID: 33863473 No abstract available.
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr, Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG. Voorhees PM, et al. Among authors: anderson ld jr. Lancet Haematol. 2023 Oct;10(10):e825-e837. doi: 10.1016/S2352-3026(23)00217-X. Epub 2023 Sep 11. Lancet Haematol. 2023. PMID: 37708911 Clinical Trial.
Evolutionary thanatology.
Anderson JR, Biro D, Pettitt P. Anderson JR, et al. Philos Trans R Soc Lond B Biol Sci. 2018 Sep 5;373(1754):20170262. doi: 10.1098/rstb.2017.0262. Philos Trans R Soc Lond B Biol Sci. 2018. PMID: 30012748 Free PMC article.
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma.
Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, Ross M, Scolyer RA, Yoon CH, Poklepovic A, Rutkowski P, Anderson JR, Ahsan S, Ibrahim N, M Eggermont AM. Luke JJ, et al. Among authors: anderson jr. Future Oncol. 2020 Jan;16(3):4429-4438. doi: 10.2217/fon-2019-0666. Epub 2019 Dec 24. Future Oncol. 2020. PMID: 31870188
Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease.
Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. Crist WM, et al. Among authors: anderson jr. J Clin Oncol. 2001 Jun 15;19(12):3091-102. doi: 10.1200/JCO.2001.19.12.3091. J Clin Oncol. 2001. PMID: 11408506 Clinical Trial.
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: anderson ld jr. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Among authors: anderson ld jr. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28. Lancet Oncol. 2024. PMID: 38821074 Review.
2,096 results